BC Week In Review | Mar 2, 2009
Company News

Nostrum, Institute of Microbial Technology deal

Nostrum received an exclusive, worldwide license from the institute to develop and commercialize Caerulomycin A , a bipyridyl immunosuppressant. Further terms were not disclosed. Caerulomycin A will be the first immunosuppressant in Nostrum's pipeline. The biotech...
Items per page:
1 - 1 of 1